Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Uni-Bio Science Group Ltd. ( (HK:0690) ).
Uni-Bio Science Group Limited has signed a tripartite strategic cooperation agreement with the National Engineering Research Center for Cell Growth Factor Drugs and Protein Formulations of Wenzhou Medical University and the Wenzhou Ouhai District People’s Government to deepen collaboration in regenerative medicine. The partners plan to establish a Uni-Bio–WMU joint innovation laboratory for translational medicine, combining research, industrial capabilities and government policy support to develop new growth-factor-based therapies and delivery systems for conditions including NASH, asthma and bone tissue repair. Backed by the China Gene Valley platform and WMU’s globally recognized expertise in cell growth factor drugs, the initiative is expected to boost Uni-Bio’s R&D efficiency, expand clinical applications of its existing products, strengthen its position in the EGF/FGF segment and accelerate commercialization of its innovative pipeline, thereby enhancing its long-term competitiveness and value for shareholders.
The most recent analyst rating on (HK:0690) stock is a Hold with a HK$0.12 price target. To see the full list of analyst forecasts on Uni-Bio Science Group Ltd. stock, see the HK:0690 Stock Forecast page.
More about Uni-Bio Science Group Ltd.
Uni-Bio Science Group Limited is a Hong Kong–listed biopharmaceutical company focused on innovative biologics, particularly cell growth factor drugs, for indications in dermatology, ophthalmology and metabolic diseases. Its portfolio includes products such as GeneTime and GeneSoft, and it targets large chronic disease markets where there is substantial unmet clinical need.
Average Trading Volume: 6,784,165
Technical Sentiment Signal: Buy
Current Market Cap: HK$691M
Learn more about 0690 stock on TipRanks’ Stock Analysis page.